AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Fampridine, used for improving walking in multiple sclerosis, may also enhance working memory in individuals with schizophrenia or depression.

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...

No approved drug in the U.S. has been able to fully address these symptoms. While second generation antipsychotics offer ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie ABBV said that its Phase 2 trial ...